3SBio Inc. (HKG:1530)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 49.99B +65.7% |
| Revenue (ttm) | 19.69B +94.3% |
| Net Income | 9.44B +305.8% |
| EPS | 3.82 +303.6% |
| Shares Out | 2.50B |
| PE Ratio | 5.24 |
| Forward PE | 15.73 |
| Dividend | 0.25 (1.20%) |
| Ex-Dividend Date | Jul 21, 2026 |
| Volume | 21,762,533 |
| Average Volume | 29,892,122 |
| Open | 20.00 |
| Previous Close | 20.16 |
| Day's Range | 19.53 - 20.28 |
| 52-Week Range | 11.10 - 36.80 |
| Beta | 0.56 |
| RSI | 35.30 |
| Earnings Date | Aug 21, 2026 |
About 3SBio
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. ... [Read more]
Financial Performance
In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.
Financial numbers in CNY Financial StatementsNews
Pfizer Signs $6B Deal with 3SBio for China-Based Cancer Drug
American drug giant Pfizer ($PFE) has entered into a $6 billion exclusive licensing deal with China’s 3SBio Inc. ($HK:1530) for its experimental cancer drug, SSGJ-707. According to the terms of…